Cargando…

Model‐based Meta‐Analysis on the Efficacy of Pharmacological Treatments for Idiopathic Pulmonary Fibrosis

Recently, the US Food and Drug Administration (FDA) approved the first two drugs (pirfenidone and nintedanib) indicated for the treatment of idiopathic pulmonary fibrosis (IPF). The purpose of this analysis was to leverage publicly available data to quantify comparative efficacy of compounds that ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Phyllis, Bax, Leon, Chen, Chunlin, Zhang, Nancy, Huang, Shu‐Pang, Soares, Holly, Rosen, Glenn, AbuTarif, Malaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658284/ https://www.ncbi.nlm.nih.gov/pubmed/28699195 http://dx.doi.org/10.1002/psp4.12227

Ejemplares similares

Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six‐Minute Walk Test
por: Hamuro, Lora, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
por: Zhu, Li, et al.
Publicado: (2018)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
por: Millan-Billi, Paloma, et al.
Publicado: (2018)

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects
por: Garimella, Tushar, et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
por: Mai, Tu H., et al.
Publicado: (2023)

Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
por: Yin, Ophelia, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

The Efficacy of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis
por: Choi, Hee Eun, et al.
Publicado: (2023)

Idiopathic pulmonary fibrosis: Current and future treatment
por: Glass, Daniel S., et al.
Publicado: (2022)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Smoking and Idiopathic Pulmonary Fibrosis
por: Oh, Chad K., et al.
Publicado: (2012)

Autophagy in Idiopathic Pulmonary Fibrosis
por: Patel, Avignat S., et al.
Publicado: (2012)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Epidemiology of idiopathic pulmonary fibrosis
por: Ley, Brett, et al.
Publicado: (2013)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

Management of Idiopathic Pulmonary Fibrosis
por: Pleasants, Roy, et al.
Publicado: (2019)

Treatment of Idiopathic Pulmonary Fibrosis
por: Abuserewa, Sherif T, et al.
Publicado: (2021)

Cough in Idiopathic Pulmonary Fibrosis
por: Mann, Jennifer, et al.
Publicado: (2021)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Idiopathic Pulmonary Fibrosis and Telomeres
por: Mulet, Alba, et al.
Publicado: (2022)

Living with idiopathic pulmonary fibrosis
por: Kirby, Tony
Publicado: (2021)

Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine
por: Myllärniemi, Marjukka, et al.
Publicado: (2015)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
por: Serra López-Matencio, José M., et al.
Publicado: (2021)

Network Pharmacology-Based Mechanistic Investigation of Jinshui Huanxian Formula Acting on Idiopathic Pulmonary Fibrosis
por: Liu, Tiantian, et al.
Publicado: (2021)

Investigation of the Pharmacological Effect and Mechanism of Jinbei Oral Liquid in the Treatment of Idiopathic Pulmonary Fibrosis Using Network Pharmacology and Experimental Validation
por: Zhang, Aijun, et al.
Publicado: (2022)

Network pharmacology and molecular docking to explore the pharmacological mechanism of Yifei Tongluo granules in treating idiopathic pulmonary fibrosis: A review
por: Hou, Yuan, et al.
Publicado: (2023)

Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects
por: Toyn, Jeremy H., et al.
Publicado: (2016)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Role of Osteopontin in Idiopathic Pulmonary Fibrosis
Publicado: (2005)

Advances in the management of idiopathic pulmonary fibrosis
por: Ryu, Jay H, et al.
Publicado: (2010)

Idiopathic pulmonary fibrosis with bronchogenic carcinoma
por: Nair, Girija, et al.
Publicado: (2009)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Recent Advances in Idiopathic Pulmonary Fibrosis
por: Park, Sanghoon, et al.
Publicado: (2013)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i2jue96on7tkhakf35nt4km7k2